Usefulness and limitations of taste sensors in the evaluation of palatability and taste-masking in oral dosage forms  by Haraguchi, Tamami et al.
Review
Usefulness and limitations of taste sensors in
the evaluation of palatability and taste-masking
in oral dosage forms
Tamami Haraguchi, Miyako Yoshida, Honami Kojima,
Takahiro Uchida *
School of Pharmaceutical Science, MukogawaWomen’s University, 11-68 Koshien 9-bancho, Nishinomiya, 663-
8179, Japan
A R T I C L E I N F O
Article history:
Received 31 August 2015
Received in revised form 26
February 2016
Accepted 2 March 2016
Available online 7 April 2016
A B S T R A C T
The purpose of this review is to discuss the advantages and limitations of taste sensors in
the evaluation of the taste of palatability of different oral dosage forms. First, we consider
some ways in which the palatability of various pharmaceutical formulations including orally
disintegrating tablets (ODTs) are tested using two different taste sensors. Second, we focus
on the evaluation of palatability of ODTs.We compare the usefulness of three pieces of ap-
paratus for estimating the disintegration time of ODTs. Finally, we compare the characteristics
of the two taste sensors in the evaluation of palatability of various kinds of drug formulations.
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Of the various types of formulation on the pharmaceutical
market, solid oral forms (e.g. tablets, capsules) are the most
common.These formulations have many advantages, such as
dose accuracy and relatively high stability, and also offer pos-
sibilities for modifying the drug release profile in order to delay
or sustain a therapeutic effect. Their palatability, however,
especially if they have a bitter taste, is also important in
maintaining patient adherence and thereby allowing effec-
tive pharmacotherapy to be attained [1,2].
Even plain tablets may be associated with problems such
as difficulty in swallowing, not only in pediatric or geriatric
populations but also for handicapped or bedridden patients.
This may be due to large tablets sticking to the throat mucosa,
causing irritation of the pharyngeal region, coughing or choking.
One way to eliminate such problems is the use of the orally
disintegrating tablet (ODT) [3–7]. The most important advan-
tages of the ODT are quick disintegration after contact with
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saliva in the mouth, facilitating swallowing, and ease of de-
livery, with no need for water to wash down the drug, thus
increasing patient adherence.
As leading formulation of ODT, Zydis® [8], or WOWTAB
(without water tablet) were developed and commercialized.
Nowadays, many ODTs are available [9–13], owing to various
manufacturing technologies developed by many researchers
[14–21].The developers of pediatric medicines particularly focus
on issues of palatability for compliance reason [22,23]. Mini-
sized ODTs have now been developed [24,25] and their
usefulness recently evaluated.
ODTs are not only of particular benefit to patients with poor
swallowing ability, but also to populations with busy lives, as
they can be taken at any time and in any place. In some cases,
however, palatability issues such as the bitterness or astrin-
gency of the active ingredient may decrease adherence, since
the acute drug concentration reached in the oral cavity can be
extremely high due to the immediate disintegration of the tablet
in saliva. Therefore, taste-masking technology must be in-
volved in the design of ODT formulations if the active ingredient
is very bitter or astringent. The oral disintegration time of an
ODT is a critical factor determining its palatability, rapid dis-
integration in the oral cavity being an essential feature of
ODTs.
The quantitative evaluation of palatability is now an im-
portant component in the process of formulation development
for various types of oral formulation, including liquids. Human
sensation test is a major method to evaluate palatability of oral
formulations [26–30]. However, the use of human volunteers
for taste-testing requires the volunteers to be accurate and
precise, while ethical issues may prevent human taste-
testing of some active drugs, e.g. anti-neoplastics. The use of
an artificial taste sensor removes these difficulties. We have
used the taste sensor to evaluate the bitterness of many kinds
of medicines (both basic and acidic drugs) and have demon-
strated its ability to predict accurately the bitterness intensity
experienced by human senses [31–52].The sensor is now avail-
able worldwide.
2. Evaluation of taste including bitterness or
astringency of medicines
2.1. Insent taste-sensing system
The first taste sensor, composed of lipid/polymer membrane
was developed byToko [53], and is nowmarketed as the Insent
taste-sensing system (Intelligent SensorTechnology Inc.,Atsugi,
Japan) [54–56] (Fig. 1). The taste sensor output exhibits differ-
ent patterns for chemical substances that have different taste
qualities, i.e. bitterness, sourness, saltiness, umami and sweet-
ness. We have previously evaluated the bitterness of various
medicines and amino acids using this system and suggested
that the sensormay be useful to predict quantitatively the bit-
terness ofmedicines [31–33].Antibiotics including clarithromycin
dry syrup, have been evaluated using this system, and a good
correlation was obtained between the results of human gus-
tatory sensation testing and the predicted bitterness intensity
calculated from the taste sensor output [34]. Aminoleban EN,
an elemental diet containing a large quantity of branched chain
amino acids (BCAAs) which have a bitter taste, was also suc-
cessfully evaluatedusing this system [35,36].Kataoka et al. [39,40]
evaluated bottled nutritive drinks using this system and found
that the bitterness or sourness predicted by taste sensor output
correlated well with the results obtained from human sensa-
tion testing. Not only the taste of medicines but also the
suppression of unpleasant taste could be predicted by this
system.Tsuji et al. [41] and Ishizaka et al. [42] reported on the
Fig. 1 – Measurement procedure of Insent taste-sensing system.
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bitterness-suppressing effect of the jellies using this system,
whileTokuyamaet al. [43] used it to demonstrate that L-Ornithine
suppresses the bitterness of BCAA solutions. Hashimoto et al.
[44] demonstrated a method for predicting the bitterness-
suppressing effect of sweeteners on a famotidine formulation
using the sweetness responsive sensor.
2.2. α-ASTREE electronic tongue
A quantitative taste sensor, the α-ASTREE electronic tongue
(Alpha MOS, Toulouse, France) is able to evaluate the overall
taste of product by using the output value from different elec-
trodes [50–52,57–62] (Fig. 2).This taste sensor consists of an array
of seven liquid cross-sensitive electrodes or sensors based on
the ChemFET technology (Chemical modified field effect tran-
sistor), an auto-sampler, and associated interface electronic
module. In the presence of dissolved compounds, a potentio-
metric difference is measured between each of the seven
sensors and the Ag/AgCl reference electrode. Each sensor has
a specific organic membrane,which interacts with ionic, neutral
and chemical compounds present in the sample solution. Any
interaction at the membrane interface is detected by the sensor
and converted into an electronic signal.The taste sensor output
is used to calculate the Euclidian distance, a variable used to
quantify the taste of the sample medium [57].Tokuyama E et al.
[50] predicted the bitterness intensity of famotidine ODTs using
this electronic tongue, and demonstrated a good correlation
between the taste predicted by principal component analysis
and the Euclidean distance obtained and bitterness intensi-
ties obtained in the human sensation test. Ito et al. [51] predicted
the bitterness of H1-antihistamines and the masking effects
of sweeteners using this electronic tongue.Maniruzzaman et al.
[58–60], Wei et al. [61] and Nakamura et al. [62] also used this
electronic tongue as an in vitro taste assessment tool.
3. Evaluation of ODTs
3.1. Disintegration time
In Japanese pharmacopoeia (JP), ODTs are described as tablets
that rapidly dissolve or disintegrate in the mouth. However,
no definition of the disintegration time is given and no method
is specified for measurement.
Three different pieces of apparatus for estimating disinte-
gration time aremarketed in Japan, (1) ODT-101 (Toyama Sangyo
Co., Ltd., Osaka), (2) TRI-CORPTESTER (Okada Seiko Co., Ltd.,
Tokyo) and (3) OD-mate (Higuchi Inc., Tokyo).
3.1.1. ODT-101
The disintegration testing apparatus ODT-101 was developed
by Narazaki and Harada et al. [45,63–65]. An ODT sample is
placed on a stainless plate.Weight is provided to the shaft which
is capable of moving in the vertical direction and rotating.The
liquid surface of the test medium (450 mL purified water) is
automatically adjusted by a pump so that the water level is
slightly below the lower face of the porous plate. The liquid
temperature is set to 37 °C. The ODT is sandwiched between
the rotating weight and the stainless plate such that the load
and shear force can be applied to the ODT. Simultaneously, the
block is immersed in the test medium and the water level of
the test medium increases. The ODT then absorbs the test
medium by capillary suction, resulting in disintegration. The
effects of load, shear, and wetting reproduce the conditions in
the oral cavity in which an ODT becomes wet with saliva and
is lightly ground between the tongue and upper jaw.
The disintegration times of propiverine hydrochloride ODTs
[45] ambroxol tablets [66] were measured using the ODT-101,
and the results showed good agreement with the results of
human sensation tests.
3.1.2. TRI-CORPTESTER
Hoashi et al. [67] developed a simple test apparatus to evalu-
ate the disintegration time of rapidly disintegrating tablets
(RDTs). This apparatus consists of a simple device, which pro-
vides a similar environment to that of the oral cavity, and has
been commercialized by Okada Seiko Co., Ltd. (Tokyo, Japan)
as TRI-CORPTESTER. The device is composed of two meshes;
a lower mesh, on which the ODT is placed, and an upper mesh,
attached to holders, which is in contact with the ODT and on
which artificial saliva is dripped from above. The disintegra-
tion time is measured as the time elapsed until the tablet
completely disintegrates and the twomeshes touch each other.
Yoshita et al. [68] reported that the in vitro disintegration time
Fig. 2 – Evaluation of ebastine orally disintegrating tablets using α-ASTREE electronic tongue [Ref. 52].
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BLOSTER®M (Elmet Eisai Co., Ltd.) 15–30 (s) ODT-101 [64]
Famotidine D tablet (Nichi-Iko Pharm. Co., Ltd.)
GASTER®D (Astellas Pharma Inc.)
GASRICK®D (Sawai Pharm. Co., Ltd.)
Famotidine OD tablet [YD] (Yoshindo Inc.)
STOMARCON®D (Taisho Pharm. Ind. Ltd.)
Ambroxol
15 mg
Mucosolvan® (Teijin Pharma Ltd.) 20–400 (s) ODT-101 [66]
Ponophen® (Aska Pharmaceutical Co., Ltd.)
Coughnol (Nichi-Iko Pharmaceutical Co., Ltd.)
Nontas® (Ono Pharmaceutical Co., Ltd.)
Pulsmarin®A (Takata Seiyaku Co., Ltd.)
Fuzuleban (Tatsumi Ltd.)
Grinkool® (Nippon Chemiphar Co., Ltd.)
Ambroxol hydrochloride tablets 15 mg [Ze] (Zensei Pharm. Ind. Co., Ltd.)
Ambroxol hydrochloride tablets 15 mg [Sawai] (Sawai Pharm. Co., Ltd.)
Ambroxol hydrochloride tablets 15 mg [Ch] ((Mylan Seiyaku Ltd.)
Lansoprazole Takepron® OD (Takeda Pharmaceutical Co., Ltd.) 25 (s) TRI-CORPTESTER [67]
Triazoram Triazolam tab. [EMEC] (Elmet Eizai Co., Ltd.) 10 (s)
Enalapril Enalapril M tab. [EMEC] (Elmet Eizai Co., Ltd.) 10 (s)
Famotidine Gaster® D (Astellas Pharma Inc.) 10 (s)
Brotizolam Lendormin® D (Nippon Boehringer Ingelheim Co., Ltd.) 15 (s)
Amoldipine
besilate
Amlodin® OD tablets 5 mg, 25 mg (Dainippon Sumitomo Pharma
Co., Ltd.)
18 (s) TRI-CORPTESTER [68]
AMLODIPINE-ODTABLETS 2.5 mg (Towa Pharmaceutical Co., Ltd.) 17 (s)
AMLODIPINE-ODTABLETS 5 mg (Towa Pharmaceutical Co., Ltd.) 20 (s)
Amlodipine 2.5 mg (Nippon Chemiper Co., Ltd.) 15 (s)
Amlodipine 5 mg (Nippon Chemiper Co., Ltd.) 24 (s)
Donepezil
hydrochloride
Aricept® D tablets 5 mg (Eisai Co., Ltd./Pfizer Japan Inc.) 5 (s)
Voglibose BASEN® ODTablets 0.2 mg (Takeda Pharmaceutical Co., Ltd.) 29 (s)
Brotizolam Lendormin D tablets 0.25 mg (Boehringer Ingelheim Japan Inc.) 13 (s)
BROTIZOLAM (Teva Pharma Japan Inc.) 13 (s)
Ebastine EBASTEL® (Dainippon Sumitomo Pharma Co., Ltd.) 17 (s)
Famotidine Gaster® D tablets 10 mg (Astellas Pharma Inc.) 19 (s)
Gaster® D tablets 20 mg (Astellas Pharma Inc.) 27 (s)
Irsogladine
malate
Gaslon N® OD tablets 2 mg, 4 mg (Nippon Shinyaku Co., Ltd.) 28 (s)
Tamsulosine
hydrochloride
Harnal D tablets 0.1 mg (Astellas Pharma Inc.) 10 (s)
Harnal D tablets 0.2 mg (Astellas Pharma Inc.) 31 (s)
TAMSLON-ODTABLETS 0.1 mg (Towa Pharmaceutical Co., Ltd.) 17 (s)
TAMSLON-ODTABLETS 0.2 mg (Towa Pharmaceutical Co., Ltd.) 24 (s)
Lansoprazole Takepron® OD tablets 15 mg (Takeda Pharmaceutical Co., Ltd.) 24 (s)
Takepron® OD tablets 30 mg (Takeda Pharmaceutical Co., Ltd.) 32 (s)
Polaprezinc Promac® D tablets 75 (Zeria Pharmaceutical Co., Ltd.) 9 (s)
Magnesium
oxide
Magmitt Tab 250 mg (Kyowa Chemical Industry Co., Ltd.) 9 (s)
Risperidone Magmitt Tab 330 mg (Kyowa Chemical Industry Co., Ltd.) 12 (s)
RISPERDAL® ODTablets 1 mg (Japan Pharmaceutical Co., Ltd.) 24 (s)
RISPERDAL® ODTablets 2 mg (Japan Pharmaceutical Co., Ltd.) 27 (s)







Amlodine® OD 5 mg (Dainippon Sumitomo Pharm. Co., Ltd.) and 9
generic products










Aricept® D 5 mg (Eisai Co., Ltd.) and 8 generic products 10–60 (s) OD-mate [72,73]
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of ODTs measured using TRI-CORPTESTER is a good reflec-
tion of the disintegration time in the oral cavity. Matsui et al.
[69] also used this method to confirm the disintegration time
was within 30s, as recommended by the FDA.
3.1.3. OD-mate
Kakutani et al. [70] developed a disintegration method for ODTs
which was more similar to the human sensory test than the
JP disintegration test. The method was commercialized by
Higuchi Inc. (Tokyo, Japan) as the OD-mate. ODT is placed on
a stainless mesh in a flat-bottomed test tube corresponding
to the tongue and compressed by two weights (30 g inner weight
and 100 g outer weight) corresponding to the upper palate.Test
media (10mL or 20mL) replicates the inside of themouth. Using
this apparatus, disintegration time of amlodipine ODTs [71],
ebastine ODTs [52], famotidine ODTs [49] have been evalu-
ated by Uchida et al. In all cases, a good correlation was obtained
between predicted disintegration time and that measured by
human testing. This apparatus was also used for donepezil
ODTs to evaluate disintegration time by Hazekawa et al. [72,73].
3.2. Combined taste sensor and apparatus to estimate
disintegration time of ODTs
While human gustatory sensation testing is the major method
for the in-vivo evaluation of palatability, this method is asso-
ciated with difficulties and limitations, as mentioned above.
A well-established statistical method is required to over-
come errors and variability between volunteers within the limits
of threshold taste perceptions. Pediatric formulations cannot
be tested by pediatric volunteers for ethical reasons.Taste sensor
systems which can predict human taste accurately are re-
quired as alternative methods for the evaluation of palatability.
Taste masking is almost always necessary for ODTs because
most active pharmaceutical ingredients produce an unpleas-
ant taste sensation, such as bitterness, when they dissolve in
the oral cavity.Therefore, ODT formulations are required which
disintegrate quickly but without expressing bitterness.The com-
bination of taste-sensing system and an apparatus to estimate
disintegration time to predict the palatability of ODTs has been
reported in several papers.The combination of the Insent taste-
sensing system and OD-mate was reported by Uchida et al. [71]
and Yoshida et al. [49], while Haraguchi et al. [52] reported a
combination of the α-ASTREE electronic tongue and the OD-
mate. Table 1 shows the list of evaluated ODTs using systems
for estimating disintegration time and taste.
4. Conclusion
Woerts et al. [74] have conducted a comparative study of the
Insent taste-sensing system and α-ASTREE electronic tongue
for pharmaceutical formulations.Those authors reported that
both systems have their merits and limitations.The Insent taste-
sensing system, in which each taste sensor membrane responds
to a particular taste, is highly skilled in the quantitative evalu-
ation of taste, such as bitterness intensity. However, some
substances are not detected by this system. On the other hand,
α-ASTREE electronic tongue is particularly good at evaluating
overall taste. It is also capable of qualitative evaluation by com-
paring Euclidean distances, representing the similarity of tastes.
From our previous studies, solifenacine succinate has been
evaluated by both Insent taste-sensing system and α-ASTREE
electronic tongue [47]. However, the taste sensor output pro-
duced by ebastine was too low for the bitterness of the
formulations to be evaluated [52].
Thus, although the combination of a taste-sensing system
and an apparatus to estimate disintegration time would be
useful for predicting the palatability of ODTs, we have to select
the appropriate devices for combination based on the char-
acteristics of the formulation and its ingredients.
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